XYZAL Drug Patent Profile

When do Xyzal patents expire, and what generic alternatives are available?

Xyzal is a drug marketed by Chattem Sanofi and is included in four NDAs. There is one patent protecting this drug and two Paragraph IV challenges.

The generic ingredient in XYZAL is levocetirizine dihydrochloride. Fifty-three suppliers are listed for this compound. Additional details are available on the levocetirizine dihydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Xyzal

A generic version of XYZAL was approved as levocetirizine dihydrochloride by SYNTHON BV on November 26^th, 2010.

Summary for XYZAL

US Patents:	0
Applicants:	1
NDAs:	4

Paragraph IV (Patent) Challenges for XYZAL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
XYZAL	Oral Solution	levocetirizine dihydrochloride	0.5 mg/mL	022157	1	2009-01-14
XYZAL	Tablets	levocetirizine dihydrochloride	5 mg	022064	1	2007-12-17

US Patents and Regulatory Information for XYZAL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chattem Sanofi	XYZAL	levocetirizine dihydrochloride	SOLUTION;ORAL	022157-001	Jan 28, 2008		DISCN	Yes	No
Chattem Sanofi	XYZAL ALLERGY 24HR	levocetirizine dihydrochloride	TABLET;ORAL	209089-001	Jan 31, 2017		OTC	Yes	Yes
Chattem Sanofi	XYZAL	levocetirizine dihydrochloride	TABLET;ORAL	022064-001	May 25, 2007		DISCN	Yes	No
Chattem Sanofi	XYZAL ALLERGY 24HR	levocetirizine dihydrochloride	SOLUTION;ORAL	209090-001	Jan 31, 2017		OTC	Yes	Yes	8,633,194		Y

International Patents for XYZAL

See the table below for patents covering XYZAL around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	8140
Australia	544066
Australia	8023182
Bosnia and Herzegovina	97198
Bosnia and Herzegovina	97199
Canada	1199918	ACIDES 2-[4-(DIPHENYLMETHYL)-1-PIPERAZINYL] ACETIQUES ET LEURS AMIDES (2-[4-(DIPHENYLMETHYL)-1-PIPERAZINYL]-ACETIC ACIDS AND THEIR AMIDES)

Supplementary Protection Certificates for XYZAL

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0663828	2002C/005	Belgium		PRODUCT NAME: LEVOCETIRIZIN. DIHYDROCHLORID; NAT. REGISTRATION: 194 IS 90 F 3 20011022; FIRST REGISTRATION: DE 49904.00.00 20010103
0663828	0490019-7	Sweden		PRODICT NAME: LEVO-CETIRIZIN OCH SALTER DAERAV; NAT REGISTRATION NO/DATE: 20039 20040423; FIRST REGISTRATION: DE 49903.00.00 20010103
0058146	SPC/GB01/052	United Kingdom		SPC/GB01/052:, EXPIRES: 20070205
0663828	C00663828/01	Switzerland		PRODUCT NAME: LEVOCETIRIZIN; REGISTRATION NO/DATE: OICM 55754 20010926
0663828	CR 2002 00006	Denmark		PRODUCT NAME: LEVOCETIRIZIN OG FARMACEUTISK ACCEPTABLE SALTE DERAF; NAT. REG. NO/DATE: 32719 20011008; FIRST REG. NO/DATE: EU 49903.00.00, 49904.00.00 20010103
0663828	CA 2002 00006	Denmark

Last updated: February 3, 2026

What Is the Market Position of XYZAL?

XYZAL (levocetirizine dihydrochloride) is an antihistamine marketed by UCB. Primarily prescribed for allergic rhinitis and chronic urticaria, it has a share in the global allergy therapeutics market. Its revenue peaked around 2018 and has since stabilized due to market saturation and competitive pressure from both generic and branded rivals.

How Does the Regulatory Environment Affect XYZAL?

The drug has received approval in multiple regions including the US, EU, and Asia. In the US, the FDA approved XYZAL in 2007; however, UCB's patent expired in 2017, leading to increased generic competition. In the EU, patent expiry occurred earlier, and generic versions entered the market between 2015 and 2018. Regulatory approvals continue to impact price, market exclusivity, and R&D investment strategies.

What Are the Patent and Patent Expiry Dates?

UCB's patent for XYZAL was granted in 2007 and expired around 2017 in the US. Extended patent protections and formulations offered limited exclusivity until expiration.[1] Generic manufacturers gained market access post-expiry, reducing revenue margins. No recent patent filings for new formulations or indications suggest limited pipeline activity for XYZAL.

How Competitive Is the Market?

The allergy medication market features multiple antihistamines, including cetirizine, levocetirizine (XYZAL), loratadine, and fexofenadine. After patent expiration, generic versions of XYZAL entered the market, impacting revenue streams. Competitors offer similar efficacy at lower prices, constraining market share for branded XYZAL.

What Are the R&D and Pipeline Prospects?

UCB has limited current R&D efforts dedicated specifically to XYZAL. The company has shifted focus toward other immunology and neurology therapies, with minimal pipeline innovation around antihistamines. No recent filings indicate upcoming formulations or new indications that could extend product life cycle.

How Do Financials Reflect Market Dynamics?

UCB's revenues from XYZAL have declined post-patent expiry. Sales figures in the US dropped by approximately 40% in the two years following patent expiry. Overall, the drug now accounts for a minor share of UCB's portfolio. Operating margins have contracted due to increased generic competition and pricing pressures.

What Are the Key Investment Risks?

• Patent challenges: Early patent expiry opens doors for generics.
• Market saturation: Limited room for volume growth, especially in mature markets.
• Pipeline scarcity: Lack of new formulations or indications reduces future growth potential.
• Pricing pressure: Increasing access to generics drives down prices.
• Brand loyalty decline: Physicians and patients shifting towards cost-effective generics.

How Could Future Scenarios Develop?

If market trends continue, XYZAL's revenue is likely to decline further, pressured by generic competition and reduced marketing focus. Conversely, if UCB invests in line extensions, combination products, or novel formulations, there could be opportunities to regain market share or extend differentiation—although no evidence currently supports this.

Key Takeaways

• XYZAL benefits from a broad approval base but faces major revenue decline following patent expiration.
• Market saturation and generic competition significantly limit growth prospects.
• Limited pipeline activity reduces strategic options for revenue revitalization.
• Financial impact on UCB's portfolio is notable but not material relative to company size.
• Investment risks remain centered around patent cliffs, commoditization, and the lack of innovation.

FAQs

1. What factors led to the decline in XYZAL sales after patent expiry?
The entry of generic competitors post-2017 reduced pricing power and market share for branded XYZAL, leading to sales decline.

2. Are there ongoing patent filings for newer versions of XYZAL?
No recent patent filings suggest UCB is not actively developing new formulations or indications for XYZAL.

3. What alternative therapies are gaining market share over XYZAL?
Generic cetirizine, loratadine, and fexofenadine have expanded their share due to lower costs and comparable efficacy.

4. Could regulatory changes benefit XYZAL in emerging markets?
Potentially, if regulatory authorities prioritize data exclusivity or delay generic approvals; however, current trends favor generics.

5. What strategic options does UCB have for XYZAL?
Options include developing combination therapies, reformulating for new indications, or discontinuing investment if the market does not justify further R&D.

---

[1] Patent data sources and regional approval timelines are compiled from UCB regulatory filings and publicly available patent registries.